T47D/TR-1

16022513, human breast, polygonal epithelia

• Codice UNSPSC: 41106514

Proprietà

• Nome del prodotto: T47D/TR-1, 16022513, from human breast
• Origine biologica: human breast
• Modalità di accrescimento: Adherent
• Morfologia: polygonal epithelia
• tecniche: cell culture | mammalian: suitable
• Condizioni di spedizione: dry ice
• Temperatura di conservazione: −196°C

Descrizione

Descrizione generale

T47D/TR-1 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells. T47D/TR-1 cells are growth inhibited by fulvestrant. Oestrogen receptor.

Descrizione della linea cellulare

The T47D/TR-1 is a breast cancer cell line resistant to tamoxifen. The T47D/TR-1 cell line has been established by long term treatment of T47D/S2 cells with 1 μM tamoxifen. Clonal selection was performed in medium without tamoxifen. After growth in presence of 1 μM tamoxifen for 10 months, the growth rate was similar to the parental cells.

Terreno di coltura

RPMI 1640 w/o Phenol Red (R7509) + 2% FBS (F2442) + 2.5 mM Ala-Gln (G8541) + 8μg/ml Insulin (I9278)

Mantenimento delle subcolture

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x 10, 000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C. Recommend media changes every 2-3 days.

Altre note

Cultures from PHE Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.

Citazione

If use of this culture results in a scientific publication, it should be cited in the publication as: T47D/TR-1 (ECACC 16022513)

Esclusione di responsabilità

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.